<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN" "JATS-journalpublishing1-4.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.4" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">ojped</journal-id>
      <journal-title-group>
        <journal-title>Open Journal of Pediatrics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2160-8776</issn>
      <issn pub-type="ppub">2160-8741</issn>
      <publisher>
        <publisher-name>Scientific Research Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.4236/ojped.2026.165066</article-id>
      <article-id pub-id-type="publisher-id">ojped-153699</article-id>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
        <subj-group>
          <subject>Medicine</subject>
          <subject>Healthcare</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Infectious Embryofoetopathies: Situation Analysis at the Charles DE GAULLE Paediatric University Hospital in Ouagadougou (Burkina Faso)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kabore/Ouedraogo</surname>
            <given-names>Aissata</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Youmbi</surname>
            <given-names>Geovannie</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Togueyeni/Tamini</surname>
            <given-names>Laure</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Konate</surname>
            <given-names>Barguissa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>YE/Ouattara</surname>
            <given-names>Diarra</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> Service de pediatrie, CHU Pédiatrique Charles DE GAULLE, Ouagadougou, Burkina Faso </aff>
      <aff id="aff2"><label>2</label> Departement de Pediatrie, Universite Joseph Ki-Zerbo, Ouagadougou, Burkina Faso </aff>
      <author-notes>
        <fn fn-type="conflict" id="fn-conflict">
          <p>The authors declare no conflicts of interest regarding the publication of this paper.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>04</day>
        <month>09</month>
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>09</month>
        <year>2026</year>
      </pub-date>
      <volume>16</volume>
      <issue>05</issue>
      <fpage>671</fpage>
      <lpage>682</lpage>
      <history>
        <date date-type="received">
          <day>04</day>
          <month>07</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>09</month>
          <year>2026</year>
        </date>
        <date date-type="published">
          <day>07</day>
          <month>09</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2026 by the authors and Scientific Research Publishing Inc.</copyright-statement>
        <copyright-year>2026</copyright-year>
        <license license-type="open-access">
          <license-p> This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link> ). </license-p>
        </license>
      </permissions>
      <self-uri content-type="doi" xlink:href="https://doi.org/10.4236/ojped.2026.165066">https://doi.org/10.4236/ojped.2026.165066</self-uri>
      <abstract>
        <p><bold>Introduction:</bold> Infectious embryofetopathies are infections mainly caused by pathogens of the TORCH group, transmitted from the mother to the fetus during pregnancy and which can have an impact on the product of conception. They represent a major public health problem because of their impact on neonatal morbidity and mortality. <bold>Objective:</bold> To take stock of infectious embryofetopathies in children hospitalized at CHUP CDG between July 1, 2021 and June 30, 2024. <bold>Method:</bold> We conducted a retrospective, descriptive and analytical cross-sectional study that involved the records of children hospitalized for infectious embryofetopathies between July 1, 2021 and June 30, 2024. <bold>Results</bold>: We included in our study 80 children hospitalized for embryofetopathy with an IgG positivity rate of 1.5%. There were 86.25% of newborns; male sex represented 62.50%. 51.25% of mothers had performed syphilis serology during pregnancy but none of them had performed the other serologies of the TORCH group; 86.25% of children were born at term. The main signs and symptoms found on admission were respiratory distress in 36.25% of cases, fever and jaundice in 27.50% of cases each; 65% of children had a visible malformation and the main internal anomalies objectified by imaging were cardiac anomalies in 56.28% of cases. The mortality rate during our study was 31.25%. Also, our study shows an association between positivity for anti-rubella IgG and death, but it does not establish that rubella is the cause of the malformations or the adverse outcome. <bold>Conclusion:</bold> It is important to screen for infectious embryofetopathies during pregnancy with the aim of caring for mothers in order to limit the occurrence of these pathologies in the newborn.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated" xml:lang="en">
        <kwd>Embryofetopathy</kwd>
        <kwd>TORCH</kwd>
        <kwd>Toxoplasmosis</kwd>
        <kwd>Rubella</kwd>
        <kwd>CMV</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Introduction</title>
      <p>Infectious embryofetal diseases are a major public health problem due to their impact on neonatal morbidity and mortality [<xref ref-type="bibr" rid="B1">1</xref>]. </p>
      <p>These infections, transmitted from mother to fetus during pregnancy, are mainly caused by pathogens of the TORCH group (Toxoplasmosis, other infections including Syphilis, Rubella, Cytomegalovirus, Herpes simplex). </p>
      <p>Among these pathologies, congenital toxoplasmosis most often results from the transplacental transmission of the parasite after a primary maternal infection [<xref ref-type="bibr" rid="B2">2</xref>]. In Africa, very little information is available, but a study carried out in Morocco found a prevalence of 4 - 8/10,000 live births [<xref ref-type="bibr" rid="B3">3</xref>]. </p>
      <p>Another pathology is congenital syphilis, which is also a major public health problem in the world [<xref ref-type="bibr" rid="B4">4</xref>]. It is one of the target diseases for triple elimination with HIV and hepatitis by 2030 [<xref ref-type="bibr" rid="B5">5</xref>].</p>
      <p>However, the pathology that causes more mortality is congenital rubella. According to the WHO, rubella is the leading cause of vaccine-preventable birth defects. About 100,000 newborns are born with congenital rubella syndrome (CRS) [<xref ref-type="bibr" rid="B6">6</xref>]. Due to its scale, it is the subject of special global surveillance by the WHO. Several countries, including Burkina Faso, have been designated for this monitoring [<xref ref-type="bibr" rid="B7">7</xref>][<xref ref-type="bibr" rid="B8">8</xref>].</p>
      <p>The CHUP CDG is involved in this surveillance with screening serology testing and the reporting of cases, particularly the reporting of newborn cases. The aim of our work is to study the clinical aspects of children with positive serology for these infectious embryofetopathies.</p>
    </sec>
    <sec id="sec2">
      <title>2. Materials and Methods</title>
      <p>This was a retrospective, cross-sectional, descriptive and analytical study that concerned the files of children hospitalized for infectious embryofetopathies between July 1, 2021 and June 30, 2024, <italic>i.e.</italic> 3 years.</p>
      <p>Included in our study were children’s records containing positive screening serology for infectious embryofetopathies. Children of all ages were screened upon admission to the pediatric emergency department. All jaundiced newborns were systematically screened in the neonatal unit. A literature review collected clinical data (anthropometric parameters at birth, neonatal history, visible malformations, jaundice), paraclinical data (results of requested serology, other orientation examinations) and the immediate evolution of hospitalized children. Some data were collected from neonatal and infant hospital registers. The positivity thresholds are those of the analysis laboratory of the Charles DE GAULLE pediatric university hospital.</p>
      <p>This data, collected using a written form, was entered and analyzed using a computer with the Epi-info software in its version 7.2.2.6.</p>
      <p>The chi-square test (<italic>χ</italic><sup>2</sup>) was used to look for a statistical relationship between the different parameters. The difference was significant when the P-value was less than 0.05.</p>
      <p>Operational definitions: Depending on the titer of the antibodies measures (IgG and IgM) performed was considered such as:</p>
      <p>Low IgG if IgG ≤ 300 IU/ml;High IgG if IgG between 301 IU/ml and 500 IU/ml;Very high IgG if IgG &gt; 500 IU/ml;Any positive case of IgM was considered a progressive infection;A suspected case of embryofetopathy is a case with a positive IgG test.</p>
    </sec>
    <sec id="sec3">
      <title>3. Results</title>
      <sec id="sec3dot1">
        <title>3.1. Frequency of Testing</title>
        <p>During our study, 5999 children were hospitalized in the 2 units; 91 children screened for infectious embryofetal disease (<italic>i.e.</italic> a screening frequency of 1.51%) and 80 children were included, from which 49 in the neonatology department and 31 in the infant’s department. 11 files were not included due to incompleteness.</p>
      </sec>
      <sec id="sec3dot2">
        <title>3.2. Socio-Demographic Characteristics</title>
        <p>The mean age of the children was 53.42 days with extremes of 1 and 1080 days, the sex ratio was 1.6. <bold>Table 1</bold> illustrates the socio-demographic characteristics of the children.</p>
        <p><bold>Table 1.</bold> Distribution of 80 children hospitalized for embryofetal disease by socio-demographic characteristics.</p>
        <table-wrap id="tbl1">
          <label>Table 1</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Socio-d</bold>
                  <bold>e</bold>
                  <bold>mographic profile</bold>
                </td>
                <td>
                  <bold>Frequency</bold>
                  <bold>(n)</bold>
                </td>
                <td>
                  <bold>Percentage</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <bold>Age range (in days)</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>≤28</td>
                <td>69</td>
                <td>86.25</td>
              </tr>
              <tr>
                <td>&gt;28</td>
                <td>11</td>
                <td>13.75</td>
              </tr>
              <tr>
                <td>
                  <bold>Gender</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Male</td>
                <td>50</td>
                <td>62.50</td>
              </tr>
              <tr>
                <td>Female</td>
                <td>30</td>
                <td>37.50</td>
              </tr>
              <tr>
                <td>
                  <bold>Residency</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Urban</td>
                <td>34</td>
                <td>42.50</td>
              </tr>
              <tr>
                <td>Rural</td>
                <td>46</td>
                <td>57.50</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>More than 86% of the children screened were newborns.</p>
      </sec>
      <sec id="sec3dot3">
        <title>3.3. Clinical Aspects</title>
        <p><bold>Medical history</bold><bold>Pregnancy follow-up</bold></p>
        <p>In our series, there was no history of stillbirths but 14 mothers or 17.50% had miscarriages. None of the mothers had diabetes, high blood pressure or HIV/AIDS, had reported repeated infections or fever during pregnancy. No notion of inbreeding had been found between the parents. Syphilis serology testing was performed in 41 mothers during pregnancy (51.25%) and was positive in 2 mothers (4.87%). No mother had performed the other serology testings in the TORCH group. The average number of antenatal visits performed by mothers was 3.78 ± 1.34 with extremes of 0 and 7. </p>
        <p><bold>Perinatal history</bold></p>
        <p>The mean birth weight was 2529.50 g ± 601.21 g with extremes of 990 g and 3800 g. In our series, 21.25% of children were hypotrophic at birth. <bold>Table 2</bold> shows a distribution of children according to perinatal history.</p>
        <p><bold>Table 2.</bold> Distribution of 80 children hospitalized for embryofetal disease based on perinatal history.</p>
        <table-wrap id="tbl2">
          <label>Table 2</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Perinatal history</bold>
                </td>
                <td>
                  <bold>Frequency</bold>
                  <bold>(n)</bold>
                </td>
                <td>
                  <bold>Percentage</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <bold>Gestational age</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>≥37 WA</td>
                <td>69</td>
                <td>86.25</td>
              </tr>
              <tr>
                <td>[32 WA - 37 WA]</td>
                <td>10</td>
                <td>12.50</td>
              </tr>
              <tr>
                <td>[28 WA - 32 WA]</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <bold>Birth Weight</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>&lt;2500 g</td>
                <td>32</td>
                <td>40</td>
              </tr>
              <tr>
                <td>≥2500 g</td>
                <td>48</td>
                <td>60</td>
              </tr>
              <tr>
                <td>
                  <bold>Birth size</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>&lt;45 cm</td>
                <td>20</td>
                <td>25</td>
              </tr>
              <tr>
                <td>≥45 cm</td>
                <td>60</td>
                <td>75</td>
              </tr>
              <tr>
                <td>
                  <bold>Birth PC</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>&lt;30 cm</td>
                <td>17</td>
                <td>18.92</td>
              </tr>
              <tr>
                <td>≥30 cm</td>
                <td>63</td>
                <td>81.08</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>WA = weeks of amenorrhea; 86% of the children were born at term.</p>
        <p><bold>Main signs and symptoms on admission</bold></p>
        <p>The signs and symptoms found during the admission examination are summarized in <bold>Table 3</bold>. A patient could present several signs.</p>
        <p><bold>Table 3.</bold> Distribution of 80 children hospitalized for embryofetal disease according to the signs at admission.</p>
        <table-wrap id="tbl3">
          <label>Table 3</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Signs and symptoms on admission</bold>
                </td>
                <td>
                  <bold>Frequency</bold>
                  <bold>(n)</bold>
                </td>
                <td>
                  <bold>Percentage</bold>
                </td>
              </tr>
              <tr>
                <td>Respiratory distress</td>
                <td>29</td>
                <td>36.25</td>
              </tr>
              <tr>
                <td>Fever</td>
                <td>22</td>
                <td>27.50</td>
              </tr>
              <tr>
                <td>Jaundice</td>
                <td>22</td>
                <td>27.50</td>
              </tr>
              <tr>
                <td>Hypotonia</td>
                <td>10</td>
                <td>12.50</td>
              </tr>
              <tr>
                <td>Heart murmur</td>
                <td>10</td>
                <td>12.50</td>
              </tr>
              <tr>
                <td>Polypnea</td>
                <td>6</td>
                <td>7.50</td>
              </tr>
              <tr>
                <td>Pallor</td>
                <td>3</td>
                <td>3.75</td>
              </tr>
              <tr>
                <td>Hypothermia</td>
                <td>2</td>
                <td>2.50</td>
              </tr>
              <tr>
                <td>Limb malformation</td>
                <td>2</td>
                <td>2.50</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Respiratory distress was the most common sign at 36.25%.</p>
        <p><bold>Visible deformities</bold></p>
        <p>The physical examination also reported birth defect in the children. A total of 89 visible birth defect were found in 52 children, <italic>i.e.</italic> a frequency of 65%. A child could have several visible birth defect at different locations. <bold>Table 4</bold> shows the distribution of visible birth defect according to location.</p>
        <p><bold>Table 4.</bold> Visible birth defect found in 52 children.</p>
        <table-wrap id="tbl4">
          <label>Table 4</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Location</bold>
                </td>
                <td>
                  <bold>Frequency (n)</bold>
                </td>
                <td>
                  <bold>Percentage</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <bold>Skull</bold>
                </td>
                <td>
                  <bold>10</bold>
                </td>
                <td>
                  <bold>12</bold>
                  <bold>.</bold>
                  <bold>50</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <bold>Face</bold>
                </td>
                <td>
                  <bold>25</bold>
                </td>
                <td>
                  <bold>41</bold>
                  <bold>.</bold>
                  <bold>25</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <italic>Cleft lip and palate</italic>
                </td>
                <td>12</td>
                <td>15</td>
              </tr>
              <tr>
                <td>
                  <italic>Microphthalmia</italic>
                </td>
                <td>5</td>
                <td>6.25</td>
              </tr>
              <tr>
                <td>
                  <italic>Micrognathism</italic>
                </td>
                <td>3</td>
                <td>3.75</td>
              </tr>
              <tr>
                <td>
                  <italic>Anophthalmia</italic>
                </td>
                <td>2</td>
                <td>2.50</td>
              </tr>
              <tr>
                <td>
                  <italic>Low implanted ears</italic>
                </td>
                <td>2</td>
                <td>2.50</td>
              </tr>
              <tr>
                <td>
                  <italic>Facial dysmorphia</italic>
                </td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <bold>Neck</bold>
                </td>
                <td>
                  <bold>1</bold>
                </td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <bold>Thorax</bold>
                </td>
                <td>
                  <bold>3</bold>
                </td>
                <td>3.75</td>
              </tr>
              <tr>
                <td>
                  <bold>Spine</bold>
                </td>
                <td>
                  <bold>6</bold>
                </td>
                <td>
                  <bold>7</bold>
                  <bold>.</bold>
                  <bold>50</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <italic>Spina bifida</italic>
                </td>
                <td>5</td>
                <td>6.25</td>
              </tr>
              <tr>
                <td>
                  <italic>Sacred dimple</italic>
                </td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <bold>Abdomen</bold>
                </td>
                <td>
                  <bold>2</bold>
                </td>
                <td>2.50</td>
              </tr>
              <tr>
                <td>
                  <bold>Limbs</bold>
                </td>
                <td>
                  <bold>35</bold>
                </td>
                <td>
                  <bold>45</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <italic>Clubfoot</italic>
                </td>
                <td>16</td>
                <td>20</td>
              </tr>
              <tr>
                <td>
                  <italic>Polydactyly</italic>
                </td>
                <td>8</td>
                <td>10</td>
              </tr>
              <tr>
                <td>
                  <italic>Syndactyly</italic>
                </td>
                <td>3</td>
                <td>3.75</td>
              </tr>
              <tr>
                <td>
                  <italic>Foot embankment</italic>
                </td>
                <td>2</td>
                <td>2.50</td>
              </tr>
              <tr>
                <td>
                  <italic>Shortened pelvic limbs</italic>
                </td>
                <td>2</td>
                <td>2.50</td>
              </tr>
              <tr>
                <td>
                  <italic>Knee recurvatum</italic>
                </td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <italic>Main bot</italic>
                </td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <italic>Typing</italic>
                </td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <italic>Femoral hypoplasia</italic>
                </td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <bold>Urogenital</bold>
                </td>
                <td>
                  <bold>7</bold>
                </td>
                <td>
                  <bold>8</bold>
                  <bold>.</bold>
                  <bold>75</bold>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p><bold>Interna</bold><bold>l</bold><bold>Birth defect</bold></p>
        <p>Imaging examinations, including ultrasound and computed tomography, detected internal malformations listed in <bold>Table 5</bold>.</p>
        <p><bold>Table 5.</bold> Distribution of internal birth defect in children suffering from Embryofoetopathy.</p>
        <table-wrap id="tbl5">
          <label>Table 5</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Objective anomalies Imaging</bold>
                </td>
                <td>
                  <bold>Frequency</bold>
                  <bold>(n)</bold>
                </td>
                <td>
                  <bold>Percentage</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <bold>Brain abnormalities</bold>
                </td>
                <td>
                  <bold>10</bold>
                </td>
                <td>
                  <bold>12</bold>
                  <bold>.</bold>
                  <bold>5</bold>
                </td>
              </tr>
              <tr>
                <td>Hydrocephalus</td>
                <td>4</td>
                <td>5</td>
              </tr>
              <tr>
                <td>Hydranencephaly</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>Ventricular ectasia</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>Choroidal plexus cyst</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>Holoprosencephaly</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>Arachnoid cyst</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>Agenesis of the corpus callosum</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <bold>Cardiac abnormalities</bold>
                </td>
                <td>
                  <bold>45</bold>
                </td>
                <td>
                  <bold>56</bold>
                  <bold>.</bold>
                  <bold>25</bold>
                </td>
              </tr>
              <tr>
                <td>Patent ductus arteriosus</td>
                <td>13</td>
                <td>16.25</td>
              </tr>
              <tr>
                <td>Ventricular septal defect</td>
                <td>8</td>
                <td>10</td>
              </tr>
              <tr>
                <td>Permeable Foramen Ovale</td>
                <td>8</td>
                <td>10</td>
              </tr>
              <tr>
                <td>Inter atrial septum aneurysm</td>
                <td>7</td>
                <td>8.75</td>
              </tr>
              <tr>
                <td>Atrial septal defect</td>
                <td>5</td>
                <td>6.25</td>
              </tr>
              <tr>
                <td>Ventricular atrio duct</td>
                <td>3</td>
                <td>3.75</td>
              </tr>
              <tr>
                <td>Single ventricle + malposition of the large arterial trunks</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>
                  <bold>Urogenital abnormalities</bold>
                </td>
                <td>
                  <bold>7</bold>
                </td>
                <td>
                  <bold>8</bold>
                  <bold>.</bold>
                  <bold>75</bold>
                </td>
              </tr>
              <tr>
                <td>Sigmoid kidneys</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>Single kidney</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>Multicystic kidney</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>Ectopic kidney (pelvic position)</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
              <tr>
                <td>Incunosecrotal hernia</td>
                <td>2</td>
                <td>2.50</td>
              </tr>
              <tr>
                <td>Bilateral renal impairment</td>
                <td>1</td>
                <td>1.25</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Cardiac abnormalities were the most common with 56.25% of cases.</p>
      </sec>
      <sec id="sec3dot4">
        <title>3.4. Screening for Embryofetal Diseases</title>
        <p>In our series, 20 children had IgG positive for toxoplasmosis and rubella, seven (7) children had IgG positive for both toxoplasmosis and CMV, and 21 children had IgG positive for both rubella and CMV.</p>
        <p><bold>Toxoplasmosis serology</bold></p>
        <p>Toxoplasmosis serology was performed in 73 children (91.25%) with IgG positive in 22 patients (30.13%). The IgM was positive in one patient, <italic>i.e.</italic> 1.37%. <bold>Table 6</bold> illustrates the distribution of children according to toxoplasmosis serology.</p>
        <p><bold>Table 6.</bold> Distribution of 22 children with positive toxoplasmosis serology.</p>
        <table-wrap id="tbl6">
          <label>Table 6</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>IgG positive levels</bold>
                  <bold>of</bold>
                  <bold>Toxoplasmosis</bold>
                </td>
                <td>
                  <bold>Frequency (n)</bold>
                </td>
                <td>
                  <bold>Percentage</bold>
                </td>
              </tr>
              <tr>
                <td>0 - 100</td>
                <td>8</td>
                <td>36.36</td>
              </tr>
              <tr>
                <td>101 - 200</td>
                <td>5</td>
                <td>22.72</td>
              </tr>
              <tr>
                <td>201 - 300</td>
                <td>3</td>
                <td>13.63</td>
              </tr>
              <tr>
                <td>301 - 400</td>
                <td>1</td>
                <td>4.54</td>
              </tr>
              <tr>
                <td>401 - 500</td>
                <td>4</td>
                <td>18.18</td>
              </tr>
              <tr>
                <td>&gt;500</td>
                <td>1</td>
                <td>4.54</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>In our series, 6 children had a serology greater than 300.</p>
        <p><bold>Rubella serology</bold></p>
        <p>Rubella serology was performed in 76 children (95%) with IgG positive in 67 children (88.15%). None of the children had positive IgM. <bold>Table 7</bold> shows the distribution of 67 children hospitalized with infectious embryofetal disease by rubella-positive IgG level.</p>
        <p><bold>Table 7.</bold> Distribution of the 67 children hospitalized for embryofetal disease with positive rubella serology.</p>
        <table-wrap id="tbl7">
          <label>Table 7</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Positive Rubella IgG levels</bold>
                </td>
                <td>
                  <bold>Frequency (n)</bold>
                </td>
                <td>
                  <bold>Percentage</bold>
                </td>
              </tr>
              <tr>
                <td>0 - 100 IU/ml</td>
                <td>36</td>
                <td>53.73</td>
              </tr>
              <tr>
                <td>101 - 200 IU/ml</td>
                <td>10</td>
                <td>14.92</td>
              </tr>
              <tr>
                <td>201 - 300 IU/ml</td>
                <td>8</td>
                <td>11.94</td>
              </tr>
              <tr>
                <td>301 - 400 IU/ml</td>
                <td>4</td>
                <td>5.97</td>
              </tr>
              <tr>
                <td>401 - 500 IU/ml</td>
                <td>5</td>
                <td>7.46</td>
              </tr>
              <tr>
                <td>&gt;500 IU/ml</td>
                <td>4</td>
                <td>5.97</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>In our series, 13 children had a serology level greater than 300.</p>
        <p><bold>CMV Serology</bold></p>
        <p>CMV serology was performed in 33 children (41.25%) with positive IgG in all children and IgM positive in two children (6.06%). <bold>Table 8</bold> shows the distribution of 33 children hospitalized with infectious embryofetal disease based on the level of rubella-positive IgG.</p>
        <p><bold>Table 8.</bold> Distribution of the 33 children hospitalized for embryofetal disease with positive CMV serology.</p>
        <table-wrap id="tbl8">
          <label>Table 8</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>CMV-positive Ig G levels</bold>
                </td>
                <td>
                  <bold>Frequency</bold>
                  <bold>(n)</bold>
                </td>
                <td>
                  <bold>Percentage</bold>
                </td>
              </tr>
              <tr>
                <td>0 - 100 IU/ml</td>
                <td>15</td>
                <td>45.45</td>
              </tr>
              <tr>
                <td>101 - 200 IU/ml</td>
                <td>5</td>
                <td>15.15</td>
              </tr>
              <tr>
                <td>201 - 300 IU/ml</td>
                <td>5</td>
                <td>15.15</td>
              </tr>
              <tr>
                <td>301 - 400 IU/ml</td>
                <td>2</td>
                <td>6.06</td>
              </tr>
              <tr>
                <td>401 - 500 IU/ml</td>
                <td>2</td>
                <td>6.06</td>
              </tr>
              <tr>
                <td>&gt;500 IU/ml</td>
                <td>4</td>
                <td>12.12</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>In our series, 8 children had a serology level greater than 300.</p>
      </sec>
      <sec id="sec3dot5">
        <title>3.5. Evolution</title>
        <p>In our series, 55 children (68.75%) had a favorable outcome with outpatient follow-up and 25 children (30%) died during hospitalization. </p>
        <p>For all 80 children screened, the diagnosis of discharge was probable infectious embryofetopathy. Factors associated with congenital rubella are listed in <bold>Table 9</bold>.</p>
        <p><bold>Table 9.</bold> Rubella-positive IgG association and signs and symptoms. </p>
        <table-wrap id="tbl9">
          <label>Table 9</label>
          <table>
            <tbody>
              <tr>
                <td>
                </td>
                <td>
                  <bold>Rubella-positive IgG n</bold>
                  <bold>(%)</bold>
                </td>
                <td>
                  <bold>OR</bold>
                  <bold>[95% CI]</bold>
                </td>
                <td>
                  <bold>P-value</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <bold>Common Signs and Symptoms</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Respiratory distress</td>
                <td>20 (29.85)</td>
                <td>0.85 [0.19 - 3.74]</td>
                <td>0.4093</td>
              </tr>
              <tr>
                <td>Jaundice</td>
                <td>18 (26.87)</td>
                <td>1.28 [0.24 - 6.77]</td>
                <td>0.4072</td>
              </tr>
              <tr>
                <td>Fever</td>
                <td>19 (23.36)</td>
                <td>1.38 [0.26 - 7.27]</td>
                <td>0.3736</td>
              </tr>
              <tr>
                <td>
                  <bold>Common visible</bold>
                  <bold>Birth defect</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Clubfoot</td>
                <td>13 (19.40)</td>
                <td>0.84 [0.15 - 4.53]</td>
                <td>0.4074</td>
              </tr>
              <tr>
                <td>Cleft lip and palate</td>
                <td>9 (13.43)</td>
                <td>0.31 [0.06 - 1.46]</td>
                <td>0.0881</td>
              </tr>
              <tr>
                <td>
                  <bold>Cardiac abnormalities</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Yes</td>
                <td>36 (53.73)</td>
                <td>0.58 [0.13 - 2.51]</td>
                <td>0.2477</td>
              </tr>
              <tr>
                <td>No</td>
                <td>31 (46.27)</td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>
                  <bold>Brain malformations</bold>
                </td>
                <td>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Yes</td>
                <td>
                </td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>No</td>
                <td>6 (8.96)</td>
                <td>0</td>
                <td>0.2282</td>
              </tr>
              <tr>
                <td>
                  <bold>Evolution</bold>
                </td>
                <td>61 (91.04)</td>
                <td>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Favourable development</td>
                <td>46 (68.66)</td>
                <td>0</td>
                <td>
                  <bold>0</bold>
                  <bold>.</bold>
                  <bold>0216</bold>
                </td>
              </tr>
              <tr>
                <td>Death</td>
                <td>21 (31.34%)</td>
                <td>
                </td>
                <td>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Deaths were associated with rubella-positive serology (P = 0.0216).</p>
      </sec>
    </sec>
    <sec id="sec4">
      <title>4. Discussion</title>
      <p>Our study has some limitations. These include the absence of systematic maternal TORCH serology, limited CMV screening, the lack of confirmatory tests such as PCR, and the possible persistence of maternal IgG in the infant.</p>
      <sec id="sec4dot1">
        <title>4.1. Clinical and Paraclinical Aspects</title>
        <p><bold>Medical history</bold></p>
        <p>The mean number of antenatal consultations (ANCs) performed by mothers was 3.78 ± 1.34 with extremes of 0 and 7 years. In our series, 70% of mothers had had no more than four (4) ANCs out of a number of eight (8) requested by the WHO. This inadequacy in pregnancy monitoring could be explained by the low attendance of health services by the population, despite the free care introduced in Burkina Faso.</p>
        <p>For the assessment of infectious embryofetal diseases in the TORCH group, only syphilitic serology was performed in 51.25%. Our results are similar to those of Nacro <italic>et</italic><italic>al</italic><italic>.</italic> in 2023 in Ouagadougou, which, during a study on clinically visible congenital malformations, had found a maternal screening rate for syphilitic serology at 42.22% [<xref ref-type="bibr" rid="B9">9</xref>]. </p>
        <p>In our series, prematurity was present in 13.75% of cases. Indeed, in the literature, prematurity is found in cases of congenital rubella and congenital CMV infection. Our results are similar to those of Pathirana <italic>et</italic><italic>al</italic><italic>.</italic> in 2019 in South Africa who had regained prematurity in 18.88% in congenital CMV infection [<xref ref-type="bibr" rid="B10">10</xref>].</p>
        <p>Motaze <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B11">11</xref>] in 2019 in South Africa. Putri <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B12">12</xref>] in 2019 also in Indonesia had found prematurity in 31% and 34% respectively in congenital rubella.</p>
        <p>This difference in rates could be explained by the fact that serologies for the detection of infectious embryofoetal diseases are not systematically carried out in cases of prematurity in our context.</p>
        <p><bold>Admission Signs</bold></p>
        <p>The most common sign and symptom encountered on admission in our series was respiratory distress in 36.25% of cases. Our results are similar to those of Putri <italic>et</italic><italic>al</italic><italic>.</italic> in 2019 in Indonesia who had found respiratory distress in 46% of cases in congenital CMV infection [<xref ref-type="bibr" rid="B12">12</xref>]. This result can be explained by the fact that cardiac abnormalities, which in most cases manifest themselves as respiratory distress and are among the most common malformations in congenital CMV infection but also in congenital rubella [<xref ref-type="bibr" rid="B8">8</xref>][<xref ref-type="bibr" rid="B11">11</xref>][<xref ref-type="bibr" rid="B12">12</xref>]. </p>
        <p>Respiratory distress was followed in terms of frequency by jaundice, which was present in our series in 27.50% of cases. In literature, jaundice is a common sign in congenital rubella, congenital toxoplasmosis but especially in congenital CMV infection. Specifically in our series, jaundice was found in 26.27% of rubella-positive IgG-positive children, 27.27% of toxoplasmosis-positive IgG-positive children, and 45.45% of CMV-positive IgG-positive children. Nagalo <italic>et</italic><italic>al</italic><italic>.</italic> in 2020 in Burkina Faso, in a descriptive study about 2 cases of congenital toxoplasmosis, had found jaundice in the 2 cases described [<xref ref-type="bibr" rid="B13">13</xref>].</p>
        <p>Motaze <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B11">11</xref>] in 2019 in South Africa as well as Masresha <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B8">8</xref>] in 2019 in the African region, had respectively found jaundice in 7% and 12% of cases of cases in their work on congenital rubella.</p>
        <p>Concerning congenital CMV infection, the work of Putri <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B12">12</xref>]. in 2019 in Indonesia as well as those of Pathirana <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B10">10</xref>]. in 2019 in South Africa had found jaundice in respectively 21% and 23.9% of cases. </p>
        <p>Concerning congenital syphilitic infection, the work of Appalsamy <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B14">14</xref>] in 2024 in South Africa found also jaundice.</p>
        <p><bold>Visible deformities</bold></p>
        <p>In our series, microcephaly was present in 3.75% of cases. This is a sign found in the literature in cases of congenital rubella and congenital CMV infection. Motaze <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B11">11</xref>] in 2019 as well as Masresha <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B8">8</xref>] in 2019 had respectively found in their work on congenital rubella a microcephaly in 24% and 32%. </p>
        <p>Our results are much closer to those of Pathirana <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B10">10</xref>] in 2019 in South Africa, which had found microcephaly in 2.2% of cases in a study on congenital CMV infection.</p>
        <p><bold>Paraclinical aspects</bold></p>
        <p>In our series, 45 cardiac abnormalities, <italic>i.e.</italic> 72.58% of internal malformations, were objectified on cardiac Doppler ultrasound, making them the main internal malformations. These results are confirmed by the literature in which cardiac abnormalities are found in congenital rubella and in congenital CMV infection. </p>
        <p>Our results are similar to those of Motaze <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B11">11</xref>] in 2019 in South Africa as well as Masresha <italic>et</italic><italic>al</italic><italic>.</italic> [<xref ref-type="bibr" rid="B8">8</xref>] in 2019 in the African region, in their work on congenital rubella, are found in congenital rubella 71% and 22% cardiac abnormalities.</p>
        <p>Concerning congenital CMV infection, the work of Putri <italic>et</italic><italic>al</italic><italic>.</italic> in 2019 in Indonesia had found a heart anomaly in 80% of cases [<xref ref-type="bibr" rid="B12">12</xref>]. Davis <italic>et</italic><italic>al</italic><italic>.</italic> found also various birth defect Concerning congenital CMV infection [<xref ref-type="bibr" rid="B15">15</xref>]. </p>
        <p>This could be explained by the fact that embryofetal diseases occurring early in pregnancy can have an impact on organogenesis in general and more specifically on the heart.</p>
      </sec>
      <sec id="sec4dot2">
        <title>4.2. Immediate Evolution</title>
        <p>In our series, the evolution was favorable with outpatient follow-up in 70% of cases and death in 30% of cases. This could be explained by the high number in our series of cardiac abnormalities manifested by respiratory distress.</p>
        <p>The only significant associated factor is the course and more specifically death in rubella-positive IgG cases. In our series, we found a rubella-related mortality rate of 31.34%. This rate differs from that found by Motaze <italic>et</italic><italic>al</italic><italic>.</italic> in 2019 in South Africa, which had found 7% [<xref ref-type="bibr" rid="B11">11</xref>]. An improvement in the technical platform and early management of heart disease cases in our work context could improve this situation. In addition, as they do not have a maternity ward at the CHUP CDG, children are screened late for these heart diseases, thus compromising their vital prognosis.</p>
      </sec>
    </sec>
    <sec id="sec5">
      <title>5. Conclusions</title>
      <p>Our study looked at 80 cases. Half of the mothers, <italic>i.e.</italic> 51.25%, had performed syphilitic serology during pregnancy, but none of them had performed the other serologies of the TORCH group, which did not make it possible to establish the relationship between mother and child from a serological point of view.</p>
      <p>Our work shows that early detection of TORCH pathologies during pregnancy, [<xref ref-type="bibr" rid="B16">16</xref>][<xref ref-type="bibr" rid="B17">17</xref>], early care of newborns [<xref ref-type="bibr" rid="B18">18</xref>]-[<xref ref-type="bibr" rid="B20">20</xref>] and rubella vaccination in infants and girls of childbearing age, remain essential in our work context.</p>
    </sec>
    <sec id="sec6">
      <title>Author Contributions</title>
      <p>The cited authors contributed to revising the protocol and classifying the hospitalisation records.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Morsy, T., Hussein, H. and Morsy, A. (2022) Torch Infections, Pathogenicity &amp; Mortality Assessments. <italic>Journal</italic><italic>of</italic><italic>the</italic><italic>Egyptian</italic><italic>Society</italic><italic>of</italic><italic>Parasitology</italic>, 52, 53-70. https://doi.org/10.21608/jesp.2022.235777 <pub-id pub-id-type="doi">10.21608/jesp.2022.235777</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.21608/jesp.2022.235777">https://doi.org/10.21608/jesp.2022.235777</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Morsy, T.</string-name>
              <string-name>Hussein, H.</string-name>
              <string-name>Morsy, A.</string-name>
              <string-name>Infections, P</string-name>
            </person-group>
            <year>2022</year>
            <article-title>Torch Infections, Pathogenicity &amp; Mortality Assessments</article-title>
            <source>Journal of the Egyptian Society of Parasitology</source>
            <volume>52</volume>
            <pub-id pub-id-type="doi">10.21608/jesp.2022.235777</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Neu, N., Duchon, J. and Zachariah, P. (2015) TORCH Infections. <italic>Clinics</italic><italic>in</italic><italic>Perinatology</italic>, 42, 77-103. https://doi.org/10.1016/j.clp.2014.11.001 <pub-id pub-id-type="doi">10.1016/j.clp.2014.11.001</pub-id><pub-id pub-id-type="pmid">25677998</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.clp.2014.11.001">https://doi.org/10.1016/j.clp.2014.11.001</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Neu, N.</string-name>
              <string-name>Duchon, J.</string-name>
              <string-name>Zachariah, P.</string-name>
            </person-group>
            <year>2015</year>
            <article-title>TORCH Infections</article-title>
            <source>Clinics in Perinatology</source>
            <volume>42</volume>
            <pub-id pub-id-type="doi">10.1016/j.clp.2014.11.001</pub-id>
            <pub-id pub-id-type="pmid">25677998</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">El Bissati, K., Levigne, P., Lykins, J., Adlaoui, E.B., Barkat, A., Berraho, A., <italic>et al.</italic> (2018) Global Initiative for Congenital Toxoplasmosis: An Observational and International Comparative Clinical Analysis. <italic>Emerging</italic><italic>Microbes</italic><italic>&amp;</italic><italic>Infections</italic>, 7, 1-14. https://doi.org/10.1038/s41426-018-0164-4 <pub-id pub-id-type="doi">10.1038/s41426-018-0164-4</pub-id><pub-id pub-id-type="pmid">30262847</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41426-018-0164-4">https://doi.org/10.1038/s41426-018-0164-4</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Bissati, K.</string-name>
              <string-name>Levigne, P.</string-name>
              <string-name>Lykins, J.</string-name>
              <string-name>Adlaoui, E.B.</string-name>
              <string-name>Barkat, A.</string-name>
              <string-name>Berraho, A.</string-name>
            </person-group>
            <year>2018</year>
            <article-title>Global Initiative for Congenital Toxoplasmosis: An Observational and International Comparative Clinical Analysis</article-title>
            <source>Emerging Microbes &amp; Infections</source>
            <volume>7</volume>
            <pub-id pub-id-type="doi">10.1038/s41426-018-0164-4</pub-id>
            <pub-id pub-id-type="pmid">30262847</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Benhaddou-Mihoubi, N., Grange, P. and Dupin, N. (2019) Syphilis Congénitale. <italic>Revue</italic><italic>Francophone</italic><italic>des</italic><italic>Laboratoires</italic>, 2019, 60-66. https://doi.org/10.1016/s1773-035x(19)30038-3 <pub-id pub-id-type="doi">10.1016/s1773-035x(19)30038-3</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s1773-035x(19)30038-3">https://doi.org/10.1016/s1773-035x(19)30038-3</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Benhaddou-Mihoubi, N.</string-name>
              <string-name>Grange, P.</string-name>
              <string-name>Dupin, N.</string-name>
            </person-group>
            <year>2019</year>
            <article-title>Syphilis Congénitale</article-title>
            <source>Revue Francophone des Laboratoires</source>
            <volume>2019</volume>
            <pub-id pub-id-type="doi">10.1016/s1773-035x(19)30038-3</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="web">OMS. Syphilis. https://www.who.int/fr/news-room/fact-sheets/detail/syphilis</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="web">OMS. Principaux Repères sur la rubéole. https://www.who.int/fr/news-room/fact-sheets/detail/rubella</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <citation-alternatives>
          <mixed-citation publication-type="report">Ou, A.C., Zimmerman, L.A., Alexander, J.P., Crowcroft, N.S., O’Connor, P.M. and Knapp, J.K. (2024) Progress toward Rubella and Congenital Rubella Syndrome Elimination—Worldwide, 2012-2022. <italic>MMWR</italic>. <italic>Morbidity</italic><italic>and</italic><italic>Mortality</italic><italic>Weekly</italic><italic>Report</italic>, 73, 162-167. https://doi.org/10.15585/mmwr.mm7308a2 <pub-id pub-id-type="doi">10.15585/mmwr.mm7308a2</pub-id><pub-id pub-id-type="pmid">38421933</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.15585/mmwr.mm7308a2">https://doi.org/10.15585/mmwr.mm7308a2</ext-link></mixed-citation>
          <element-citation publication-type="report">
            <person-group person-group-type="author">
              <string-name>Ou, A.C.</string-name>
              <string-name>Zimmerman, L.A.</string-name>
              <string-name>Alexander, J.P.</string-name>
              <string-name>Crowcroft, N.S.</string-name>
              <string-name>Connor, P.M.</string-name>
              <string-name>Knapp, J.K.</string-name>
            </person-group>
            <year>2024</year>
            <article-title>Progress toward Rubella and Congenital Rubella Syndrome Elimination—Worldwide, 2012-2022</article-title>
            <source>MMWR. Morbidity and Mortality Weekly Report</source>
            <volume>73</volume>
            <pub-id pub-id-type="doi">10.15585/mmwr.mm7308a2</pub-id>
            <pub-id pub-id-type="pmid">38421933</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Masresha, B., Shibeshi, M., Kaiser, R., Luce, R., Katsande, R. and Mihigo, R. (2018) Congenital Rubella Syndrome in the African Region—Data from Sentinel Surveillance. <italic>Journal</italic><italic>of</italic><italic>Immunological</italic><italic>Sciences</italic>, 2, 145-149. https://doi.org/10.29245/2578-3009/2018/si.1122 <pub-id pub-id-type="doi">10.29245/2578-3009/2018/si.1122</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.29245/2578-3009/2018/si.1122">https://doi.org/10.29245/2578-3009/2018/si.1122</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Masresha, B.</string-name>
              <string-name>Shibeshi, M.</string-name>
              <string-name>Kaiser, R.</string-name>
              <string-name>Luce, R.</string-name>
              <string-name>Katsande, R.</string-name>
              <string-name>Mihigo, R.</string-name>
            </person-group>
            <year>2018</year>
            <article-title>Congenital Rubella Syndrome in the African Region—Data from Sentinel Surveillance</article-title>
            <source>Journal of Immunological Sciences</source>
            <volume>2</volume>
            <pub-id pub-id-type="doi">10.29245/2578-3009/2018/si.1122</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Narco, F. (2023) Malformations congénitales cliniquement visibles chez les enfants reçus au centre hospitalier universitaire pédiatrique Charles de Gaulle: Aspects épidémi-ologiques, cliniques et socio-environnementaux. Prospective. Université Joseph Ki-Zerbo.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Narco, F.</string-name>
            </person-group>
            <year>2023</year>
            <article-title>Malformations congénitales cliniquement visibles chez les enfants reçus au centre hospitalier universitaire pédiatrique Charles de Gaulle: Aspects épidémi-ologiques, cliniques et socio-environnementaux</article-title>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Pathirana, J., Groome, M., Dorfman, J., Kwatra, G., Boppana, S., Cutland, C., <italic>et al.</italic> (2019) Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of in Utero Human Immunodeficiency Virus (HIV) Acquisition in a High-HIV Prevalence Setting, South Africa. <italic>Clinical</italic><italic>Infectious</italic><italic>Diseases</italic>, 69, 1789-1796. https://doi.org/10.1093/cid/ciz019 <pub-id pub-id-type="doi">10.1093/cid/ciz019</pub-id><pub-id pub-id-type="pmid">30615106</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciz019">https://doi.org/10.1093/cid/ciz019</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Pathirana, J.</string-name>
              <string-name>Groome, M.</string-name>
              <string-name>Dorfman, J.</string-name>
              <string-name>Kwatra, G.</string-name>
              <string-name>Boppana, S.</string-name>
              <string-name>Cutland, C.</string-name>
              <string-name>Setting, S</string-name>
            </person-group>
            <year>2019</year>
            <article-title>Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of in Utero Human Immunodeficiency Virus (HIV) Acquisition in a High-HIV Prevalence Setting, South Africa</article-title>
            <source>Clinical Infectious Diseases</source>
            <volume>69</volume>
            <pub-id pub-id-type="doi">10.1093/cid/ciz019</pub-id>
            <pub-id pub-id-type="pmid">30615106</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Motaze, N.V., Manamela, J., Smit, S., Rabie, H., Harper, K., duPlessis, N., <italic>et al.</italic> (2019) Congenital Rubella Syndrome Surveillance in South Africa Using a Sentinel Site Approach: A Cross-Sectional Study. <italic>Clinical</italic><italic>Infectious</italic><italic>Diseases</italic>, 68, 1658-1664. https://doi.org/10.1093/cid/ciy758 <pub-id pub-id-type="doi">10.1093/cid/ciy758</pub-id><pub-id pub-id-type="pmid">30203002</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciy758">https://doi.org/10.1093/cid/ciy758</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Motaze, N.V.</string-name>
              <string-name>Manamela, J.</string-name>
              <string-name>Smit, S.</string-name>
              <string-name>Rabie, H.</string-name>
              <string-name>Harper, K.</string-name>
              <string-name>Plessis, N.</string-name>
            </person-group>
            <year>2019</year>
            <article-title>Congenital Rubella Syndrome Surveillance in South Africa Using a Sentinel Site Approach: A Cross-Sectional Study</article-title>
            <source>Clinical Infectious Diseases</source>
            <volume>68</volume>
            <pub-id pub-id-type="doi">10.1093/cid/ciy758</pub-id>
            <pub-id pub-id-type="pmid">30203002</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Putri, N.D., Wiyatno, A., Dhenni, R., Sriyani, I.Y., Dewantari, A.K., Handryastuti, S., <italic>et al.</italic> (2019) Birth Prevalence and Characteristics of Congenital Cytomegalovirus Infection in an Urban Birth Cohort, Jakarta, Indonesia. <italic>Inter</italic><italic>national</italic><italic>Journal</italic><italic>of</italic><italic>Infectious</italic><italic>Diseases</italic>, 86, 31-39. https://doi.org/10.1016/j.ijid.2019.06.009 <pub-id pub-id-type="doi">10.1016/j.ijid.2019.06.009</pub-id><pub-id pub-id-type="pmid">31207385</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijid.2019.06.009">https://doi.org/10.1016/j.ijid.2019.06.009</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Putri, N.D.</string-name>
              <string-name>Wiyatno, A.</string-name>
              <string-name>Dhenni, R.</string-name>
              <string-name>Sriyani, I.Y.</string-name>
              <string-name>Dewantari, A.K.</string-name>
              <string-name>Handryastuti, S.</string-name>
              <string-name>Cohort, J</string-name>
            </person-group>
            <year>2019</year>
            <article-title>Birth Prevalence and Characteristics of Congenital Cytomegalovirus Infection in an Urban Birth Cohort, Jakarta, Indonesia</article-title>
            <source>International Journal of Infectious Diseases</source>
            <volume>86</volume>
            <pub-id pub-id-type="doi">10.1016/j.ijid.2019.06.009</pub-id>
            <pub-id pub-id-type="pmid">31207385</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <citation-alternatives>
          <mixed-citation publication-type="report">Nagalo, K., Kaboret, S., Toguyéni, L., Attoh, A., Bélemviré, A., Sanwidi, M., <italic>et al.</italic> (2022) Congenital Toxoplasmosis or the Tip of an Iceberg. Report of Two Cases. <italic>Open Journal of Pedi</italic><italic>atrics</italic>, 12, 213-222. https://doi.org/10.4236/ojped.2022.121023 <pub-id pub-id-type="doi">10.4236/ojped.2022.121023</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4236/ojped.2022.121023">https://doi.org/10.4236/ojped.2022.121023</ext-link></mixed-citation>
          <element-citation publication-type="report">
            <person-group person-group-type="author">
              <string-name>Nagalo, K.</string-name>
              <string-name>Kaboret, S.</string-name>
              <string-name>Attoh, A.</string-name>
              <string-name>Sanwidi, M.</string-name>
            </person-group>
            <year>2022</year>
            <article-title>Congenital Toxoplasmosis or the Tip of an Iceberg</article-title>
            <source>Report of Two Cases. Open Journal of Pediatrics</source>
            <volume>12</volume>
            <pub-id pub-id-type="doi">10.4236/ojped.2022.121023</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Appalsamy, P. and Naidoo, N. (2024) Resurgence of Congenital Syphilis: A Profile of Symptomatic Newborns with Congenital Syphilis Requiring Admission to the Nursery at a Peri-Urban Regional Hospital in Kwazulu-Natal Province, South Africa. <italic>South African Journa</italic><italic>l</italic><italic>of</italic><italic>Child</italic><italic>Health</italic>, 18, e434. https://doi.org/10.7196/sajch.2024.v18i1.434 <pub-id pub-id-type="doi">10.7196/sajch.2024.v18i1.434</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7196/sajch.2024.v18i1.434">https://doi.org/10.7196/sajch.2024.v18i1.434</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Appalsamy, P.</string-name>
              <string-name>Naidoo, N.</string-name>
              <string-name>Province, S</string-name>
            </person-group>
            <year>2024</year>
            <article-title>Resurgence of Congenital Syphilis: A Profile of Symptomatic Newborns with Congenital Syphilis Requiring Admission to the Nursery at a Peri-Urban Regional Hospital in Kwazulu-Natal Province, South Africa</article-title>
            <source>South African Journal of Child Health</source>
            <volume>18</volume>
            <pub-id pub-id-type="doi">10.7196/sajch.2024.v18i1.434</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Davis, N.L., King, C.C. and Kourtis, A.P. (2017) Cytomegalovirus Infection in Pregnancy. <italic>Birth</italic><italic>Defects</italic><italic>Research</italic>, 109, 336-346. https://doi.org/10.1002/bdra.23601 <pub-id pub-id-type="doi">10.1002/bdra.23601</pub-id><pub-id pub-id-type="pmid">28398680</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/bdra.23601">https://doi.org/10.1002/bdra.23601</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Davis, N.L.</string-name>
              <string-name>King, C.C.</string-name>
              <string-name>Kourtis, A.P.</string-name>
            </person-group>
            <year>2017</year>
            <article-title>Cytomegalovirus Infection in Pregnancy</article-title>
            <source>Birth Defects Research</source>
            <volume>109</volume>
            <pub-id pub-id-type="doi">10.1002/bdra.23601</pub-id>
            <pub-id pub-id-type="pmid">28398680</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Maldonado, Y.A. and Read, J.S. (2017) Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. <italic>Pediatrics</italic>, 139, e20163860. https://doi.org/10.1542/peds.2016-3860 <pub-id pub-id-type="doi">10.1542/peds.2016-3860</pub-id><pub-id pub-id-type="pmid">28138010</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1542/peds.2016-3860">https://doi.org/10.1542/peds.2016-3860</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Maldonado, Y.A.</string-name>
              <string-name>Read, J.S.</string-name>
              <string-name>Diagnosis, T</string-name>
            </person-group>
            <year>2017</year>
            <article-title>Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States</article-title>
            <source>Pediatrics</source>
            <volume>139</volume>
            <pub-id pub-id-type="doi">10.1542/peds.2016-3860</pub-id>
            <pub-id pub-id-type="pmid">28138010</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Boudaouara, Y., Aoun, K., Maatoug, R., Souissi, O., Bouratbine, A. and Abdallah, R.B. (2018) Congenital Toxoplasmosis in Tunisia: Prenatal and Neonatal Diagnosis and Postnatal Follow-Up of 35 Cases. <italic>The</italic><italic>American</italic><italic>Journal</italic><italic>of</italic><italic>Tropical</italic><italic>Medicine</italic><italic>and</italic><italic>Hygiene</italic>, 98, 1722-1726. https://doi.org/10.4269/ajtmh.17-0580 <pub-id pub-id-type="doi">10.4269/ajtmh.17-0580</pub-id><pub-id pub-id-type="pmid">29663900</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4269/ajtmh.17-0580">https://doi.org/10.4269/ajtmh.17-0580</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Boudaouara, Y.</string-name>
              <string-name>Aoun, K.</string-name>
              <string-name>Maatoug, R.</string-name>
              <string-name>Souissi, O.</string-name>
              <string-name>Bouratbine, A.</string-name>
              <string-name>Abdallah, R.B.</string-name>
            </person-group>
            <year>2018</year>
            <article-title>Congenital Toxoplasmosis in Tunisia: Prenatal and Neonatal Diagnosis and Postnatal Follow-Up of 35 Cases</article-title>
            <source>The American Journal of Tropical Medicine and Hygiene</source>
            <volume>98</volume>
            <pub-id pub-id-type="doi">10.4269/ajtmh.17-0580</pub-id>
            <pub-id pub-id-type="pmid">29663900</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Kimberlin, D.W., Jester, P.M., Sánchez, P.J., Ahmed, A., Arav-Boger, R., Michaels, M.G., <italic>et al.</italic> (2015) Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. <italic>New</italic><italic>England</italic><italic>Journal</italic><italic>of</italic><italic>Medicine</italic>, 372, 933-943. https://doi.org/10.1056/nejmoa1404599 <pub-id pub-id-type="doi">10.1056/nejmoa1404599</pub-id><pub-id pub-id-type="pmid">25738669</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/nejmoa1404599">https://doi.org/10.1056/nejmoa1404599</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Kimberlin, D.W.</string-name>
              <string-name>Jester, P.M.</string-name>
              <string-name>Ahmed, A.</string-name>
              <string-name>Arav-Boger, R.</string-name>
              <string-name>Michaels, M.G.</string-name>
            </person-group>
            <year>2015</year>
            <article-title>Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease</article-title>
            <source>New England Journal of Medicine</source>
            <volume>372</volume>
            <pub-id pub-id-type="doi">10.1056/nejmoa1404599</pub-id>
            <pub-id pub-id-type="pmid">25738669</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <citation-alternatives>
          <mixed-citation publication-type="web">CDC (2024) STI Treatment Guidelines. Centers for Disease Control and Prevention. https://www.cdc.gov/std/treatment-guidelines/default.htm</mixed-citation>
          <element-citation publication-type="web">
            <year>2024</year>
            <article-title>STI Treatment Guidelines</article-title>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Magny, J.F. and Nicloux, M. (2020) Devenir et prise en charge du nouveau-né infecté par le cytomégalovirus. <italic>Bulletin de l</italic>’ <italic>Académie Nationale de Médecine</italic>, 204, 144-150. https://doi.org/10.1016/j.banm.2019.10.022 <pub-id pub-id-type="doi">10.1016/j.banm.2019.10.022</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.banm.2019.10.022">https://doi.org/10.1016/j.banm.2019.10.022</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Magny, J.F.</string-name>
              <string-name>Nicloux, M.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Devenir et prise en charge du nouveau-né infecté par le cytomégalovirus</article-title>
            <source>Bulletin de l’Académie Nationale de Médecine</source>
            <volume>204</volume>
            <pub-id pub-id-type="doi">10.1016/j.banm.2019.10.022</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>